Cell and Gene Therapy

Neurology Fellowship Programs

Center For Translational Neuromedicine
Division of Cell and Gene Therapy / Division of Glial Diseases and Therapeutics


Steven Goldman, M.D., Ph.D., Co-Director
Maiken Nedergaard, M.D., DMSc., Co-Director

Robert Agate, Ph.D. Aihua Yuan, Ph.D.
Romane Auvergne, Ph.D. Maria Cotrina, Ph.D.

Abdellatif Benraiss, Ph.D

Rashid Deane, B.Sc., Ph.D.

Eleanor Carson-Walter, Ph.D.

Jeff Iliff, Ph.D.

Adilia Hormigo, M.D., Ph.D. Nanhong Lou, B.Med.

Yoichi Kondo, M.D., Ph.D.

Erlend Nagelhus, M.D., Ph.D.

Joana Osorio, M.D.

Weiguo Peng, B.Med., M.Surg.

Kevin Walter, M.D.

Takahiro Takano, Ph.D.

Su Wang, B.Med., Ph.D.

Fushun Wang, Ph.D.

Martha Windrem, Ph.D.

Linhui Wang, Ph.D.

Major Clinical and Investigative Interests

The goal of our Center is to develop new approaches for treating neurological diseases, using cell and gene therapy. Our emphasis is on using these technologies to mobilize endogenous stem and progenitor cells of the adult brain and spinal cord, for purposes of structural repair. In addition, stem cell isolation and transplant strategies are also actively pursued. Our disease targets are those attributable to dysfunction or loss of single cell types, for instance dysmyelinating disease as a paradigm for the use of oligodendrocyte progenitor cells. The principal groups in the Center include Dr. Goldman, whose division focuses on neural stem biology, and Dr. Nedergaard, whose division focuses on astrocytic physiology and pathology.

Goldman (Division of Cell & Gene Therapy): Focus on cell replacement, tumorigenesis, and myelin disease

  • Molecular identification and gene expression analysis of phenotypically-restricted progenitor and glial cell types of both the fetal and adult human CNS
  • The relationship of native neural stem cells to tumor stem cells and gliomas of the adult CNS
  • Glial and oligodendrocyte progenitor-based cell therapy in models of pediatric leukodystophies
  • Development of restricted neuronal progenitor cells for transplantation and drug development, such as those generating midbrain dopaminergic neurons
  • Use of both ES cell-derived and native progenitors in neurodegenerative diseases, including Parkinson’s, ALS, and MS
  • Inducing endogenous progenitors as a means of treatment, in particular in Huntington’s disease models

Nedergaard Lab (Division of Glial Therapeutics): Focus on stroke and traumatic brain and spinal cord injury

  • The role of astrocytes in epileptogenesis and the treatment of seizure disorders
  • The contribution of astrocytes to the regulation of cerebral blood flow, especially in ischemia
  • Activity-dependent modulation of astrocytic signaling
  • The role of gliosis and glial signaling in stroke
  • Assessment of glial gene expression patterns in various disease states
  • Developing new modalities for imaging native and transplanted glial progenitors in vivo
  • Glial targeted treatment of spinal cord injury

Structure and track record: Besides the senior faculty, the unit includes over a dozen junior faculty, and a significant representation of postdoctoral fellows and students. The labs are highly collaborative, with many investigators pursuing projects between the principal lab groups. The group’s work is currently supported by 7 NIH R01 grants, as well as by a variety of foundations that include the National MS Society, New York State Stem Cell Program, CHDI Foundation, Adelson Medical Research Foundation, National Science Foundation, American Heart Association, Propionin Acidemia Foundation and the Mathers Charitable Foundation. Past and present biotech and pharmaceutical collaborators include Biogen Idec, Sanofi-Aventis, QThera, Regeneron, Merck, and others, advancing both the scope and translational intent of these studies.

Contact Person:
Steven Goldman, M.D., Ph.D.
Maiken Nedergaard, M.D., DMSc.
Phone: 585-275-9550 (Dr. Goldman)
585-273-2868 (Dr. Nedergaard)
Fax: 585-276-2298